Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-029007
Filing Date
2025-02-27
Accepted
2025-02-27 16:03:58
Documents
96
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K ntla-20241231.htm   iXBRL 10-K 3581625
2 EX-3.1 ntla-ex3_1.htm EX-3.1 105372
3 EX-4.1 ntla-ex4_1.htm EX-4.1 46895
4 EX-10.31 ntla-ex10_31.htm EX-10.31 561008
5 EX-10.32 ntla-ex10_32.htm EX-10.32 103083
6 EX-19.1 ntla-ex19_1.htm EX-19.1 93238
7 EX-21.1 ntla-ex21_1.htm EX-21.1 4888
8 EX-23.1 ntla-ex23_1.htm EX-23.1 3848
9 EX-31.1 ntla-ex31_1.htm EX-31.1 14748
10 EX-31.2 ntla-ex31_2.htm EX-31.2 14769
11 EX-32.1 ntla-ex32_1.htm EX-32.1 9240
12 GRAPHIC img110002449_0.jpg GRAPHIC 131475
13 GRAPHIC img110002449_1.jpg GRAPHIC 657246
  Complete submission text file 0000950170-25-029007.txt   16614673

Data Files

Seq Description Document Type Size
14 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ntla-20241231.xsd EX-101.SCH 1705511
99 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20241231_htm.xml XML 2577691
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37766 | Film No.: 25678591
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)